A C-peptide level of more than 20 pmol/L may indicate a lower risk for hypoglycemia among adults with type 1 diabetes, suggesting that these individuals may safely pursue tighter glycemic targets, according to findings published in Diabetic Medicine.
“Findings from [the Diabetes Control and Complications Trial] highlight that the benefit of persistent C-peptide may arise from allowing tighter glucose control with intensive treatment through protection from hypoglycemia,” Richard Oram, PhD, BMBCh, MRCP, a senior clinical instructor at the Institute of Biomedical and Clinical Science at the University of Exeter Medical School in the U.K., and colleagues wrote. “Although [the Diabetes Control and Complications Trial] provides clear evidence of benefit from preserved endogenous insulin secretion in an intensively treated trial setting, and studies of islet cell transplants show the clear benefit of restoring relatively large amounts of endogenous insulin secretion, the impact of preserved endogenous insulin in people with long-standing diabetes receiving usual clinical care is unclear.”
More here –> Healio.com
